Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

5.41
+0.11502.17%
Volume:363.48K
Turnover:1.94M
Market Cap:326.80M
PE:-1.17
High:5.41
Open:5.23
Low:5.21
Close:5.29
52wk High:9.94
52wk Low:4.27
Shares:60.46M
Float Shares:47.66M
Volume Ratio:0.53
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6291
EPS(LYR):-3.7413
ROE:-77.81%
ROA:-22.38%
PB:1.48
PE(LYR):-1.44

Loading ...

Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial

TIPRANKS
·
Apr 09

Vanda starts Thetis trial of NEREUS to curb GLP-1 therapy vomiting

Reuters
·
Apr 09

Vanda Pharmaceuticals Announces Initiation of the Thetis Study, a Clinical Trial of Nereus™ for the Prevention of Vomiting Induced by Glp-1 Receptor Agonists

THOMSON REUTERS
·
Apr 09

Vanda Pharmaceuticals Inc - Topline Results From Thetis Study Expected by Q4 2026

THOMSON REUTERS
·
Apr 09

Vanda Pharmaceuticals Inc: Phase 2 Study Succeeded and Met Its Primary Endpoint

THOMSON REUTERS
·
Apr 09

Vanda SVP, General Counsel Timothy Williams resigns effective April 10

Reuters
·
Apr 03

Ema's Chmp: Confirmed Recommendation to Refuse a Change to Marketing Authorisation for Hetlioz (Tasimelteon)

THOMSON REUTERS
·
Mar 27

Vanda Pharmaceuticals Calls for FDA Action to Accelerate Shift From Animal Testing to Human-Relevant Methods

THOMSON REUTERS
·
Mar 20

Vanda Pharmaceuticals urges FDA to revise draft guidance on non-animal testing methods

Reuters
·
Mar 20

Ema: Refusal of Change to Hetlioz Marketing Authorisation to Add Treatment of Nighttime Sleep Disturbance in Adults With Smith-Magenis Syndrome

THOMSON REUTERS
·
Mar 18

Ema: Issued Its Opinion on Hetlioz Marketing Authorisation Change After Re-Examination on 16 March

THOMSON REUTERS
·
Mar 18

Vanda Pharmaceuticals Initiated at Buy by Truist Securities

Dow Jones
·
Mar 05

Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target

MT Newswires Live
·
Mar 05

BUZZ-U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group

Reuters
·
Mar 04

BUZZ-U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy

Reuters
·
Mar 03

Vanda Wins FDA Hearing in HETLIOZ Jet Lag Approval Dispute

Reuters
·
Mar 03

Vanda Announces FDA Grants Landmark Hearing for Hetlioz® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

THOMSON REUTERS
·
Mar 03

Vanda Pharmaceuticals: Limited Downside, Pipeline-Driven Upside Supports $24 Target Price

TIPRANKS
·
Mar 02

Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone

MT Newswires Live
·
Feb 27

Ema's Chmp: Iloperidone Vanda Pharmaceuticals (Iloperidone) Received Negative Opinion From Chmp for Treatment of Schizophrenia

THOMSON REUTERS
·
Feb 27